Patient characteristics according to the BCR-ABL1/ABL ratio 3 months after starting imatinib
| BCR-ABL1/ABL at 3 mo . | ≤10% . | >10% . | P . |
|---|---|---|---|
| n (%) | 25 (63) | 15 (37) | |
| Sex, n | |||
| Boys | 14 | 11 | |
| Girls | 11 | 4 | .329 |
| Age, median (range), y | 11.3 (0.8-16.7) | 11.7 (1.9-17.3) | .561 |
| Sokal risk score* | |||
| Low | 5 | 2 | |
| Intermediate | 7 | 1 | |
| High | 13 | 12 | .170 |
| Splenomegaly | 19 (76%) | 14 (93%) | |
| Spleen size, median (range), cm below the costal margin | 5 (0-21) | 13 (0-21) | .005 |
| White blood cell count, median (range), ×109/L | 252 (16-482) | 378 (44-762) | .02 |
| BCR-ABL1/ABL at 3 mo . | ≤10% . | >10% . | P . |
|---|---|---|---|
| n (%) | 25 (63) | 15 (37) | |
| Sex, n | |||
| Boys | 14 | 11 | |
| Girls | 11 | 4 | .329 |
| Age, median (range), y | 11.3 (0.8-16.7) | 11.7 (1.9-17.3) | .561 |
| Sokal risk score* | |||
| Low | 5 | 2 | |
| Intermediate | 7 | 1 | |
| High | 13 | 12 | .170 |
| Splenomegaly | 19 (76%) | 14 (93%) | |
| Spleen size, median (range), cm below the costal margin | 5 (0-21) | 13 (0-21) | .005 |
| White blood cell count, median (range), ×109/L | 252 (16-482) | 378 (44-762) | .02 |
As applied to patients younger than 45 years of age.9